Respiratory failure & ventilation
Use of protracted continuous positive airway pressure (CPAP) as supportive treatment for COVID-19 pneumonitis and associated outcomes: a national cohort study
Main finding · Hospital mortality after subsequent IMVResult — go to the resultOdds ratio 1.4 95% CI 0.84–2.33Authors' conclusion
Protracted CPAP was used frequently for managing patients with COVID-19. Whilst it was not associated with worse outcomes for those patients who subsequently required IMV, this might be due to residual confounding and differences in processes of care.
Study context
- Population
- Adults admitted to Scottish critical care units with COVID-19 (March 1, 2020 to December 25, 2021) who received CPAP
- Participants
- 1,961 adults
- Exposure
- Protracted vs standard duration CPAP
- Protracted duration CPAPn = 733
- Outcome
- Hospital mortality after subsequent IMV
Methodological detailsmultivariable logistic regression
- Multivariable logistic regression
Main finding
As reported in the abstract
Odds ratio
1.4
95% CI 0.84–2.33
P = 0.195
By group
Protracted duration CPAP vs Standard duration CPAP
OR 1.4 (95% CI 0.84–2.33); P = 0.195
Observational data: associations, not effects.
Further findings
CPAP failure (IMV or death)
- CPAP failure
- 891 (45.4%)
- Received IMV
- 544 (27.7%)
- Died in critical care without IMV
- 347 (17.7%)
Hospital mortality, whole population
- Hospital mortality
- 41.3%
Use of protracted CPAP
- Received protracted CPAP
- 733 (37.4%)
Original publication
Use of protracted CPAP as supportive treatment for COVID-19 pneumonitis and associated outcomes: a national cohort study. Br J Anaesth. Published 25 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →